Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets

The development of pulmonary arterial hypertension (PAH) in pediatric patients has been linked to the production of the arachidonic acid metabolite, thromboxane A(2) (TxA(2)). The present study evaluated the therapeutic effect of furegrelate sodium, a thromboxane synthase inhibitor, on the developme...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirenallur-S., Dinesh K., Detweiler, Neil D., Haworth, Steven T., Leming, Jeaninne T., Gordon, John B., Rusch, Nancy J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401873/
https://www.ncbi.nlm.nih.gov/pubmed/22837860
http://dx.doi.org/10.4103/2045-8932.97605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401873/
https://www.ncbi.nlm.nih.gov/pubmed/22837860
http://dx.doi.org/10.4103/2045-8932.97605

Ejemplares similares